<DOC>
	<DOC>NCT00568074</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm速 and Glucobay速 given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.</brief_summary>
	<brief_title>Efficacy and Safety of Repaglinide, Glurenorm速 and Glucobay速 in Chinese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Gliquidone</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Type 2 diabetes No previous treatment for diabetes HbA1c: 7.012.0% Type 1 diabetes Uncontrolled treated/untreated hypertension Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results Pregnancy, breastfeeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures (adequate contraceptive measures are: sterilisation, intrauterine device (IUD), oral contraceptives or barrier methods)</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>